25 October, 2019

The life sciences are in a period of dramatic change and innovation. Developments in new technologies, such as cell therapies and gene editing, are challenging traditional IP strategies and business models.

IAM’s fourth annual Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge innovation.